Table 2.
Radiologic response as measured by the European Association of the Study of the Liver (EASL) criteria of 353 hepatocellular carcinomas treated with transarterial chemoembolization.
| Variable | Progressive disease | Stable disease | Partial response | Complete response |
|---|---|---|---|---|
| Initial response | 8 (8/353; 2.2%) | 64 (64/353; 18.1%) | 85 (85/353; 24.1%) | 196 (196/353; 55.5%) |
| Max response | 8 (8/353; 2.2%) | 38 (38/353; 10.8%) | 77 (77/353; 21.8%) | 230 (230/353; 65.2%) |
| ORR by total bilirubin | ||||
| Total bilirubin < 2 | Total bilirubin 2–3 | Total bilirubin > 3 | P-value | |
| Initial response | 0.58 | |||
| Yes | 236 (236/293; 80.5%) | 34 (34/45; 75.6%) | 9 (9/12; 75%) | |
| No | 57 (57/293; 19.5%) | 11 (11/45; 24.4%) | 3 (3/12; 25%) | |
| Max response | ||||
| Yes | 259 (259/293; 88.4%) | 36 (36/45; 80%) | 10 (10/12; 83.3%) | |
| No | 34 (34/293; 11.6%) | 9 (9/45; 20%) | 2 (2/12; 16.7%) | 0.22 |
| ORR by direct bilirubin | ||||
| Direct bilirubin < 1 | Direct bilirubin 1–2 | P-value | ||
| Initial response | 0.78 | |||
| Yes | 255 (255/318; 80.2%) | 17 (17/20; 85%) | ||
| No | 63 (63/318; 19.8%) | 3 (3/20; 15%) | ||
| Max response | >0.99 | |||
| Yes | 278 (278/318; 87.4%) | 18 (18/20; 90%) | ||
| No | 40 (40/318; 12.6%) | 2 (2/20; 10%) | ||
ORR: Overall radiologic response. Variables are expressed as raw numbers. Numbers in parentheses are proportions followed by percentages.